Skip to content

Similar metrics at other companies

ADTRAN Holdings, Inc. logo
ADTNDE — Revenue
$33.93M+24.8%
Mobileye Global Inc. logo
MBLYDE — Revenue
$77M+4.1%
Novanta logo
NOVTDE — Revenue
$36.29M+27.5%
AvePoint, Inc. logo
AVPTDE — Revenue
$16.4M+33.5%
Gentherm logo
THRMDE — Revenue
$33.63M+26.6%
Dana Incorporated logo
DANDE — Revenue
$108.5M+0.2%

Other financials

Income statement

See full
Revenue$22.7M+184%
Operating income-$60.1M-61.8%
Net income-$60.6M-78.6%
EPS (diluted)-$0.61-74.3%

Balance sheet

See full
Cash & equivalents$24.3M-39.0%
Total debt$96.5M+132,122%
Total equity$61.3M-73.2%
Total assets$287.6M-12.1%

Cash flow

See full
Operating cash flow-$44.9M-10.3%
CapEx--100%
Free cash flow-$44.9M-10.1%

Valuation

See full
Market cap$1.05B-32.6%
Enterprise value$1.12B-26.0%
P/S10.6×-5.4×

Profitability

See full
Operating margin-204.5%
Net margin-200%-219pp
FCF margin-177.1%-206pp

Returns & leverage

See full
Return on equity-136.4%-144pp
Debt / equity1.6×+1.6×
Current ratio4.9×-6.1×

Where this comes from

Reported directly by ARS Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about ARS Pharmaceuticals, Inc.'s dk — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ARS Pharmaceuticals, Inc.'s DK — revenue?
ARS Pharmaceuticals, Inc. (SPRY) reported DK — revenue of $2.78M in Q1 2026.
What does DK — revenue mean?
This metric represents the total revenue generated from product sales or service contracts within the Denmark geographic segment, net of any sales-related taxes. It serves as a key indicator of market penetration and commercial adoption of the company's therapeutic offerings in the Nordic region. Tracking this figure allows investors to assess the regional performance and growth trajectory of the company's international commercialization strategy.